Barinthus Biotherapeutics PLC Sponsored ADR (BRNS)
(Delayed Data from NSDQ)
$1.35 USD
-0.03 (-2.17%)
Updated Aug 9, 2024 01:23 PM ET
2-Buy of 5 2
F Value C Growth D Momentum D VGM
Income Statements
Fiscal Year end for Barinthus Biotherapeutics PLC Sponsored ADR falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 1 | 45 | 0 | 5 | 7 |
Cost Of Goods | 0 | 0 | 0 | 0 | 0 |
Gross Profit | 1 | 45 | 0 | 5 | 7 |
Selling & Adminstrative & Depr. & Amort Expenses | 85 | 49 | 45 | 25 | 33 |
Income After Depreciation & Amortization | -84 | -4 | -45 | -20 | -26 |
Non-Operating Income | 7 | 5 | -3 | 6 | 3 |
Interest Expense | 0 | 0 | 3 | 4 | 0 |
Pretax Income | -77 | 1 | -51 | -18 | -23 |
Income Taxes | -3 | -4 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | -2 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -73 | 5 | -51 | -18 | -23 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -73 | 5 | -51 | -18 | -21 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -78 | 0 | -45 | -20 | -25 |
Depreciation & Amortization (Cash Flow) | 5 | 4 | 1 | 0 | 0 |
Income After Depreciation & Amortization | -84 | -4 | -45 | -20 | -26 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 38.39 | 38.17 | 25.89 | NA | NA |
Diluted EPS Before Non-Recurring Items | -1.91 | 0.14 | -1.67 | NA | NA |
Diluted Net EPS (GAAP) | -1.91 | 0.14 | -1.96 | -0.69 | NA |
Fiscal Year end for Barinthus Biotherapeutics PLC Sponsored ADR falls in the month of December .
All items in Millions except EPS data.
6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | |
---|---|---|---|---|---|
Sales | NA | 0.00 | 0.00 | 0.00 | 0.33 |
Cost Of Goods | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Gross Profit | NA | 0.00 | 0.00 | 0.00 | 0.33 |
SG&A, R&D, and Dept/Amort Expenses | 0.00 | 16.92 | 19.99 | 16.10 | 26.67 |
Income After SG&A, R&D, and Dept/Amort Expenses | 0.00 | -16.92 | -19.99 | -16.10 | -26.34 |
Non-Operating Income | NA | 1.37 | 1.89 | 1.40 | 1.39 |
Interest Expense | NA | 0.01 | 0.01 | 0.01 | 0.01 |
Pretax Income | NA | -15.56 | -18.11 | -14.71 | -24.96 |
Income Taxes | NA | -0.04 | -0.82 | -0.60 | -1.14 |
Minority Interest | NA | -0.03 | 0.00 | -0.04 | -0.02 |
Investment Gains/Losses | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | NA | -15.52 | -17.29 | -14.11 | -23.82 |
Extras & Discontinued Operations | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | NA | -15.49 | -17.29 | -14.07 | -23.80 |
Earnings Per Share Data | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 |
---|---|---|---|---|---|
Average Shares | NA | 38.77 | 38.60 | 38.53 | 38.41 |
Diluted EPS Before Non-Recurring Items | NA | -0.40 | -0.45 | -0.37 | -0.62 |
Diluted Net EPS (GAAP) | NA | -0.40 | -0.44 | -0.37 | -0.62 |